Antiviral Compound Meets Phase 2 Primary Endpoint
Drug Discovery & Development
Chimerix Inc. announced positive results from a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV) disease in hematopoietic stem cell transplant (HCT) recipients. In CMX001 Study 201, a double-blind, placebo-controlled trial ...
Chimerix Antiviral Compound, CMX001, Meets CMV Phase 2 Primary Endpoint in ...MarketWatch (press release)

all 15 news articles »